Avia Pharma has signed a long-term license agreement with Endoceutics for the Nordic commercial rights to Intrarosa®.
Intrarosa® is locally administered for the treatment of vaginal atrophy.
Intrarosa® contains prasterone, an inactive steroid hormone that is converted locally inside the vaginal cells into androgens and estrogens. This intracellular production does not contribute to clinically meaningful increases in blood concentrations of estrogens.
“This is a new and very innovative product that will benefit women and address a large unmet medical need” says Jacob Calmvik, CEO of Avia Pharma. “We are also very happy to further strengthen our position as a women’s health company.”
Intrarosa was approved in the EU in January 2018 and Avia Pharma expects to launch Intrarosa® in the Nordics in mid-2018.